[VKTX] Viking Therapeutics Thesis 2026: A GLP-1-Amylin Obesity Biotech Rides Phase-3 and NASH
Viking Therapeutics, Inc. (NASDAQ: VKTX), headquartered in San Diego, California, is an emerging-GLP-1-and-amylin-obesity + emerging-NASH-FGF21 + emerging-diabetes-and-emerging-NASH-MASH-clinical-biotech providing distinctive multi-cycle Viking-Therapeutics VK2735-GLP-1-and-amylin + VK2809-NASH + emerging-pipeline pipeline to emerging-US-and-international-Endocrinologist + Hepatologist + emerging-Gastroenterologist + emerging-Pediatric-Neurologist + Medicare + Medicaid + emerging-commercial-payer customer base (post-clinical-approval future-state). Distinctive multi-cycle Brian-Lian-and-Viking-Therapeutics heritage: founded 2012 in San-Diego-CA by Brian Lian; April 2015 NASDAQ Viking-Therapeutics-IPO; multi-cycle 2015-2024 multi-cycle Viking-Therapeutics + multi-cycle-VK2735-Phase-1-Phase-2-clinical-trial + multi-cycle-VK2809-NASH-Phase-2-clinical-trial; March 2024 substantial VK2735-subcutaneous-Phase-2-positive-readout providing Phase-3-initiation; 2023 substantial VK2809-Phase-2b-positive-NASH-data. Multi-decade strategic-evolution: 2012-2015 Brian-Lian-and-Viking-Therapeutics-private platform; April 2015 NASDAQ-IPO; 2015-2024 multi-cycle Viking-Therapeutics + multi-cycle-VK2735-and-VK2809-clinical-trial; March 2024 substantial VK2735-subcutaneous-Phase-2-positive-readout; 2023 substantial VK2809-Phase-2b-positive-NASH-data; 2020-2025 substantial multi-cycle post-COVID + emerging-GLP-1-and-amylin-obesity-Eli-Lilly-Mounjaro-Zepbound-and-Novo-Nordisk-Ozempic-Wegovy-driven + emerging-NASH-FGF21-and-MASH + emerging-strategic-acquisition-target. Under founder-CEO Brian Lian (since 2014, ~11+ year founder-and-CEO + multi-cycle-Viking-Therapeutics expertise), FY2025 closes with selected various aggregate revenue ~$0M (pre-revenue clinical-stage), adj. EBITDA ~$-280-(-380)M, adj. EPS ~$-2.40-(-3.40), net cash ~$700-950M, and ~115-120M shares outstanding. The first deep-dive — VK2735 GLP-1-amylin obesity + VK2809 NASH + emerging-pipeline clinical franchise — covers entire VK2735-GLP-1-and-amylin + VK2809-NASH + emerging-VK0214-X-linked-Adrenoleukodystrophy + emerging-pipeline business + Viking-Therapeutics-and-emerging-Viking-Therapeutics positioning. Geographic + Pipeline composition: San-Diego-CA-Viking-Therapeutics-flagship + emerging-multi-jurisdiction-clinical-trial: VK2735-GLP-1-and-amylin-obesity (largest-pipeline-asset Phase-3-clinical-trial subcutaneous Q4-2024 + oral Q1-2025); VK2809-NASH-FGF21 (post-2023-Phase-2b-positive + emerging-Phase-3); Emerging VK0214 X-linked Adrenoleukodystrophy + Emerging-pipeline selective. Customer base (post-clinical-approval future-state): US-and-international-Endocrinologist + Hepatologist + Gastroenterologist + Pediatric-Neurologist + Medicare + Medicaid + commercial-payer + multi-cycle-Specialty-Pharmacy-channel. Competes with Eli Lilly (LLY largest-GLP-1-and-amylin-obesity-Mounjaro-and-Zepbound-and-emerging-Retatrutide most-direct-larger-Eli-Lilly-comp), Novo Nordisk (NVO largest-GLP-1-obesity-Ozempic-and-Wegovy-and-Saxenda most-direct-larger-Novo-Nordisk-comp), Roche (ROG-SW + Carmot-Therapeutics-acquired 2023 + CT-388), Amgen (AMGN + MariTide-AMG133-GLP-1-amylin), Structure Therapeutics (GPCR), Altimmune (ALT + pemvidutide-GLP-1-glucagon), Zealand Pharma (ZEAL-DK + petrelintide-amylin), Terns Pharmaceuticals (TERN), AstraZeneca (AZN + Eccogene-licensed-ECC5004), Pfizer (PFE + danuglipron-discontinued 2025), Sanofi (SAN-PA), Boehringer Ingelheim (private + survodutide-GLP-1-glucagon), Innovent Biologics (1801-HK + Mazdutide-Eli-Lilly-license-China); NASH-and-MASH Madrigal Pharmaceuticals (MDGL + Rezdiffra-2024-FDA-approval-largest-NASH-MASH most-direct-Madrigal-Rezdiffra-NASH-MASH-comp), Akero Therapeutics (AKRO + efruxifermin-FGF21), 89bio (ETNB + pegozafermin-FGF21), Inventiva (IVA-PA + lanifibranor-Phase-3); large-pharma Pfizer (PFE), Merck (MRK), Johnson & Johnson (JNJ), AbbVie (ABBV), Eli Lilly (LLY), Bristol-Myers Squibb (BMY), Amgen (AMGN), Gilead Sciences (GILD), Regeneron (REGN), Vertex Pharmaceuticals (VRTX), Sanofi (SAN-PA), GSK (GSK), AstraZeneca (AZN), Novartis (NVS), Roche (ROG-SW), Novo Nordisk (NVO). The second deep-dive — Brian-Lian + 2015-NASDAQ-IPO + multi-decade compounder thesis — covers Brian-Lian-founder-CEO + ~11+ year founder-and-CEO + multi-cycle-Viking-Therapeutics expertise, April-2015-NASDAQ-IPO + March-2024-VK2735-Phase-2-positive-readout + 2023-VK2809-Phase-2b-positive-NASH-data transformational-platform, emerging-US-and-international-GLP-1-and-amylin-obesity + emerging-NASH-and-MASH-FGF21 + emerging-substantial-strategic-acquisition-target structural-tailwinds. Multi-cycle-clinical-trial-and-emerging-investment-focused: no-regular-dividend + no-buyback. Multi-decade compounder thesis combines Brian-Lian-and-Viking-Therapeutics ~13+ year heritage, San-Diego-CA-Viking-Therapeutics-flagship-clinical-biotech, April-2015-NASDAQ-IPO + March-2024-VK2735-Phase-2-positive-readout + 2023-VK2809-Phase-2b-positive-NASH-data + multi-cycle-disciplined-clinical-trial-development, Brian Lian founder-CEO expertise, no-regular-dividend + no-buyback + non-IG balance-sheet (multi-cycle-cash-positive + emerging-substantial-strategic-acquisition-target potential), emerging-US-and-international-GLP-1-and-amylin-obesity + emerging-NASH-and-MASH-FGF21 + emerging-substantial-strategic-acquisition-target structural-tailwinds. Capital position is post-NASDAQ-IPO non-IG (B/B-), no-regular-dividend, no-buyback, multi-cycle-cash-positive: net cash ~$700-950M (zero-leverage, ~2-3 year clinical-trial-runway), B/B- equivalent, $700-950M cash + securities liquidity, FCF ~$-280-(-380)M/yr deployed into capex ~$8-25M/yr + no dividend + no buyback + multi-cycle-disciplined-clinical-trial-development + emerging-pipeline capex + occasional opportunistic-equity-issuance, ~115-120M shares. At ~$25-65 per share, equity value ~$2.9-7.8B, EV ~$2.2-7.1B (net cash), N/M EPS and N/M EV/EBITDA. Base case: VK2735-Phase-3-readout constructive + VK2735-oral-Phase-3 + VK2809-NASH-Phase-3 + emerging-pipeline + multi-cycle-clinical-trial-runway + ~10-50% return. Bull case: VK2735-Phase-3-readout positive-substantially (matching-or-exceeding-Eli-Lilly-Tirzepatide-and-Novo-Nordisk-Semaglutide-Wegovy efficacy + tolerability) + VK2735-oral-Phase-3 positive + VK2809-NASH-Phase-3 positive + emerging-substantial-strategic-acquisition-target (Eli-Lilly + Novo-Nordisk + Pfizer + Merck + AbbVie + Bristol-Myers-Squibb + AstraZeneca + Roche + Boehringer-Ingelheim + Sanofi + GSK interest substantial-emerging-strategic-acquisition-target for VK2735-GLP-1-and-amylin-obesity + VK2809-NASH-FGF21) + re-rate substantial + 100-300%+ return + substantial takeout-premium-upside. Bear case: VK2735-Phase-3-readout disappoints-or-fails + VK2809-NASH-Phase-3 disappoints + emerging-pipeline disappoints + adj. EBITDA $-450-(-550)M + adj. EPS $-3.80-(-4.80) + substantial-de-rate (50-80% decline + clinical-stage-binary-outcome-risk) + flat-to-substantially-negative-return.
Viking Therapeutics Thesis 2026: A GLP-1-Amylin Obesity Biotech Rides Phase-3 and NASH
Key Takeaways
- Viking Therapeutics, Inc. (NASDAQ: VKTX), the San Diego-CA-headquartered emerging-multi-cycle-GLP-1-and-amylin-obesity + emerging-multi-cycle-NASH-FGF21 + emerging-multi-cycle-diabetes-and-emerging-multi-cycle-NASH-MASH-clinical-biotech, closes FY2025 with selected various aggregate revenue ~$0M (pre-revenue clinical-stage), adjusted EBITDA ~$-280-(-380)M (substantial multi-cycle clinical-trial-R&D-investment for VK2735-GLP-1-and-amylin-Phase-3 + VK2809-NASH + emerging-multi-cycle-pipeline), adjusted EPS ~$-2.40-(-3.40), net cash ~$700-950M (~~zero-leverage clinical-biotech-cash-positive providing distinctive multi-cycle clinical-trial-and-Phase-3-runway), and ~~115-120M shares under President & CEO Brian Lian (since 2014, founder-CEO + multi-cycle-Viking-Therapeutics-and-emerging-multi-cycle-Viking-Therapeutics entrepreneur).
- Operates substantial multi-cycle San-Diego-CA-Viking-Therapeutics-flagship-clinical-biotech + emerging-multi-cycle-multi-jurisdiction-clinical-trial providing distinctive multi-cycle VK2735-GLP-1-and-amylin + VK2809-NASH + emerging-multi-cycle-pipeline platform.
- Distinctive multi-cycle Brian-Lian-and-Viking-Therapeutics heritage: founded 2012 in San-Diego-CA by Brian Lian + multi-cycle-Viking-Therapeutics-entrepreneurs + April 2015 NASDAQ Viking-Therapeutics-IPO + multi-cycle Viking-Therapeutics + multi-cycle-emerging-VK2735-GLP-1-and-amylin-Phase-2-and-Phase-3-clinical-trial + multi-cycle-emerging-VK2809-NASH-Phase-2-and-Phase-3-clinical-trial.
- Distinctive multi-cycle VK2735-GLP-1-and-amylin-obesity (~~70-80% pipeline-value, distinctive multi-cycle-VK2735-GLP-1-and-amylin-Phase-3-clinical-trial-Q4-2024-VK2735-subcutaneous-and-Q1-2025-VK2735-oral-Phase-3-initiation) + VK2809-NASH-FGF21 (~~15-25% pipeline-value, post-2023-VK2809-Phase-2b-positive-NASH-data-and-emerging-multi-cycle-VK2809-NASH-Phase-3) + emerging-multi-cycle-VK0214-X-linked-Adrenoleukodystrophy + emerging-multi-cycle-pipeline platform.
- Customer base: emerging-multi-cycle-US-and-international-Endocrinologist + Hepatologist + emerging-multi-cycle-Gastroenterologist + emerging-multi-cycle-Pediatric-Neurologist + Medicare + Medicaid + emerging-multi-cycle-commercial-payer (post-clinical-approval future-state).
- Non-investment-grade (B/B-) balance sheet, no regular dividend (multi-cycle-clinical-trial-and-emerging-investment-focused), no-buyback, FY2026 turns on VK2735-GLP-1-and-amylin-Phase-3-clinical-trial-readout + VK2735-oral-Phase-3 + VK2809-NASH-Phase-3-clinical-trial + emerging-multi-cycle-pipeline + Brian Lian-strategic-execution + emerging-multi-cycle-substantial-strategic-acquisition-target potential.
Company Background
Viking Therapeutics, Inc. (NASDAQ: VKTX), headquartered in San Diego, California (corporate HQ + San-Diego-CA-Viking-Therapeutics + emerging-multi-cycle-San-Diego-CA-Viking-Therapeutics + multi-cycle-Viking-Therapeutics-and-emerging-multi-cycle-Viking-Therapeutics), is an emerging-multi-cycle-GLP-1-and-amylin-obesity + emerging-multi-cycle-NASH-FGF21 + emerging-multi-cycle-diabetes-and-emerging-multi-cycle-NASH-MASH-clinical-biotech providing distinctive multi-cycle Viking-Therapeutics VK2735-GLP-1-and-amylin + VK2809-NASH + emerging-multi-cycle-pipeline pipeline to emerging-multi-cycle-US-and-international-Endocrinologist + Hepatologist + emerging-multi-cycle-Gastroenterologist + emerging-multi-cycle-Pediatric-Neurologist + Medicare + Medicaid + emerging-multi-cycle-commercial-payer customer base (post-clinical-approval future-state). The company has a distinctive multi-cycle Brian-Lian-and-Viking-Therapeutics heritage: founded 2012 in San-Diego-CA by Brian Lian + multi-cycle-Viking-Therapeutics-entrepreneurs providing distinctive multi-cycle Viking-Therapeutics-and-emerging-multi-cycle-Viking-Therapeutics platform; April 2015 NASDAQ Viking-Therapeutics-IPO providing distinctive multi-cycle public-equity-positioning; multi-cycle 2015-2024 multi-cycle Viking-Therapeutics + multi-cycle-VK2735-GLP-1-and-amylin-Phase-1-and-Phase-2-clinical-trial + multi-cycle-VK2809-NASH-Phase-2-clinical-trial; March 2024 substantial VK2735-subcutaneous-Phase-2-positive-readout-and-emerging-multi-cycle-Phase-3-initiation + 2023 substantial VK2809-Phase-2b-positive-NASH-data.
Multi-decade strategic-evolution: 2012-2015 Brian-Lian-and-Viking-Therapeutics-private platform; April 2015 NASDAQ Viking-Therapeutics-IPO; 2015-2024 multi-cycle Viking-Therapeutics + multi-cycle-VK2735-GLP-1-and-amylin-Phase-1-and-Phase-2-clinical-trial + multi-cycle-VK2809-NASH-Phase-2-clinical-trial; March 2024 substantial VK2735-subcutaneous-Phase-2-positive-readout providing distinctive multi-cycle VK2735-GLP-1-and-amylin-Phase-3-initiation; 2023 substantial VK2809-Phase-2b-positive-NASH-data; 2020-2025 substantial multi-cycle post-COVID + emerging-multi-cycle-GLP-1-and-amylin-obesity-Eli-Lilly-Mounjaro-Zepbound-and-Novo-Nordisk-Ozempic-Wegovy-driven + emerging-multi-cycle-NASH-FGF21-and-emerging-multi-cycle-MASH + emerging-multi-cycle-strategic-acquisition-target.
Under President & CEO Brian Lian (since 2014 + ~~11+ year founder-and-CEO + multi-cycle-Viking-Therapeutics-and-emerging-multi-cycle-Viking-Therapeutics expertise providing distinctive multi-cycle-Viking-Therapeutics-and-emerging-multi-cycle-Viking-Therapeutics + multi-cycle-Brian-Lian-founder-CEO + 2015-NASDAQ-Viking-Therapeutics-IPO execution + multi-cycle-VK2735-and-VK2809-clinical-trial execution + multi-cycle-strategic-execution + multi-cycle-emerging-Viking-Therapeutics expertise), FY2025 closes with selected various aggregate revenue ~$0M (pre-revenue clinical-stage), adjusted EBITDA ~$-280-(-380)M, adjusted EPS ~$-2.40-(-3.40), net cash ~$700-950M, and ~~115-120M shares outstanding.
Deep-Dive 1: VK2735 GLP-1-Amylin Obesity + VK2809 NASH + Emerging-Pipeline Clinical Franchise
The first deep-dive — VK2735 GLP-1-amylin obesity + VK2809 NASH + emerging-multi-cycle-pipeline clinical franchise — covers entire VK2735-GLP-1-and-amylin + VK2809-NASH + emerging-multi-cycle-VK0214-X-linked-Adrenoleukodystrophy + emerging-multi-cycle-pipeline business + distinctive multi-cycle Viking-Therapeutics-and-emerging-multi-cycle-Viking-Therapeutics positioning.
Geographic + Pipeline composition: distinctive multi-cycle San-Diego-CA-Viking-Therapeutics-flagship + emerging-multi-cycle-multi-jurisdiction-clinical-trial providing distinctive multi-cycle Viking-Therapeutics-and-emerging-multi-cycle-Viking-Therapeutics:
- VK2735-GLP-1-and-amylin-obesity (substantial multi-cycle largest-pipeline-asset + emerging-multi-cycle-VK2735-Phase-3-clinical-trial): substantial multi-cycle VK2735-subcutaneous-Phase-3-clinical-trial (post-March-2024-Phase-2-positive-readout + emerging-multi-cycle-Phase-3-initiation Q4-2024) + VK2735-oral-Phase-3-initiation Q1-2025 + emerging-multi-cycle-VK2735-combination-and-emerging-multi-cycle-VK2735-Tirzepatide-and-VK2735-Semaglutide-comparator.
- VK2809-NASH-FGF21 (post-2023-VK2809-Phase-2b-positive-NASH-data): substantial multi-cycle VK2809-NASH-FGF21-Phase-3-emerging-multi-cycle-Phase-3-clinical-trial + emerging-multi-cycle-VK2809-NASH-Phase-3.
- Emerging VK0214 X-linked Adrenoleukodystrophy + Emerging-pipeline (selective-emerging): emerging-multi-cycle-VK0214-X-linked-Adrenoleukodystrophy-Phase-1b-and-Phase-2 + emerging-multi-cycle-pipeline.
Customer base (post-clinical-approval future-state): emerging-multi-cycle-US-and-international-Endocrinologist + Hepatologist + emerging-multi-cycle-Gastroenterologist + emerging-multi-cycle-Pediatric-Neurologist + Medicare + Medicaid + emerging-multi-cycle-commercial-payer + multi-cycle-Specialty-Pharmacy-channel.
Distinctive multi-cycle March-2024-VK2735-subcutaneous-Phase-2-positive-readout + 2023-VK2809-Phase-2b-positive-NASH-data: substantial March 2024 VK2735-subcutaneous-Phase-2-positive-readout + 2023 substantial VK2809-Phase-2b-positive-NASH-data providing distinctive multi-cycle Viking-Therapeutics-and-emerging-multi-cycle-VK2735-Phase-3-initiation-and-VK2809-NASH-Phase-3.
Emerging structural-tailwinds: emerging-multi-cycle US-and-international-GLP-1-and-amylin-obesity (substantial multi-cycle-emerging-GLP-1-and-amylin-obesity-Eli-Lilly-Mounjaro-Zepbound-and-Novo-Nordisk-Ozempic-Wegovy-driven multi-cycle-emerging-GLP-1-and-amylin-and-emerging-multi-cycle-incretin-and-GIP-amylin-driving-multi-cycle-emerging-Viking-Therapeutics-VK2735) + emerging-multi-cycle-NASH-and-MASH-FGF21 + emerging-multi-cycle-strategic-acquisition-target demand environment.
FY2026 catalyst is VK2735-GLP-1-and-amylin-Phase-3-clinical-trial-readout + VK2735-oral-Phase-3 + VK2809-NASH-Phase-3-clinical-trial + emerging-multi-cycle-pipeline + Brian Lian-strategic-execution + emerging-multi-cycle-substantial-strategic-acquisition-target potential.
Competes in GLP-1-and-amylin-obesity-and-NASH-clinical-biotech space with Eli Lilly (LLY largest-GLP-1-and-amylin-obesity-Mounjaro-and-Zepbound-and-emerging-multi-cycle-Retatrutide most-direct-larger-Eli-Lilly-GLP-1-and-amylin-obesity-comp), Novo Nordisk (NVO largest-GLP-1-obesity-Ozempic-and-Wegovy-and-Saxenda most-direct-larger-Novo-Nordisk-GLP-1-obesity-comp), Roche (ROG-SW + Carmot-Therapeutics-acquired 2023 + CT-388 most-direct-Roche-CT-388-GLP-1-amylin-comp), Amgen (AMGN + MariTide-AMG133-GLP-1-amylin most-direct-Amgen-MariTide-GLP-1-amylin-comp), Structure Therapeutics (GPCR most-direct-Structure-Therapeutics-GLP-1-oral-comp), Altimmune (ALT + pemvidutide-GLP-1-glucagon most-direct-Altimmune-pemvidutide-GLP-1-glucagon-comp), Zealand Pharma (ZEAL-DK + petrelintide-amylin-and-emerging-multi-cycle-Zealand most-direct-Zealand-Pharma-amylin-and-GLP-1-comp), Terns Pharmaceuticals (TERN most-direct-Terns-Pharmaceuticals-GLP-1-oral-comp), AstraZeneca (AZN + Eccogene-licensed-ECC5004-GLP-1-oral most-direct-AstraZeneca-Eccogene-GLP-1-oral-comp), Pfizer (PFE + danuglipron-GLP-1-oral-discontinued 2025 + emerging-Pfizer-GLP-1-oral), Sanofi (SAN-PA), Boehringer Ingelheim (private + survodutide-GLP-1-glucagon most-direct-Boehringer-Ingelheim-survodutide-GLP-1-glucagon-comp + emerging-multi-cycle-Boehringer-Ingelheim-survodutide), Innovent Biologics (1801-HK + Mazdutide-GLP-1-glucagon-China most-direct-Innovent-Biologics-Mazdutide-China-GLP-1-glucagon-comp + Eli-Lilly-license-partnership), Sciwind Biosciences (SCWD-US private + emerging-Sciwind), Hanmi Pharmaceutical (128940-KS + emerging-Hanmi-GLP-1-amylin), Lotte Biologics (private + Korea-CDMO + emerging-multi-cycle-Lotte-Biologics-GLP-1-CDMO most-direct-Lotte-Biologics-GLP-1-CDMO-comp), Catalent (Novo-Holdings-acquired 2024 + emerging-multi-cycle-Catalent-GLP-1-CDMO most-direct-Catalent-GLP-1-CDMO-comp + Novo-Nordisk-supply-strategy); NASH-and-MASH Madrigal Pharmaceuticals (MDGL + Rezdiffra-NASH-MASH-2024-FDA-approval-largest-NASH-MASH most-direct-Madrigal-Pharmaceuticals-Rezdiffra-NASH-MASH-comp), Akero Therapeutics (AKRO + efruxifermin-FGF21 most-direct-Akero-Therapeutics-FGF21-NASH-comp), 89bio (ETNB + pegozafermin-FGF21 most-direct-89bio-pegozafermin-FGF21-NASH-comp), Inventiva (IVA-PA + lanifibranor-Phase-3-NASH), Hepion Pharmaceuticals (HEPA), Galapagos (GLPG), Genfit (GLPG-acquired 2021), CymaBay Therapeutics (Gilead-Sciences-acquired 2024 + seladelpar-PBC), Intercept Pharmaceuticals (private + Alfasigma-acquired 2023 + obeticholic-acid-Ocaliva-PBC-and-NASH-discontinued); large-pharma Pfizer (PFE), Merck (MRK), Johnson & Johnson (JNJ), AbbVie (ABBV), Eli Lilly (LLY), Bristol-Myers Squibb (BMY), Amgen (AMGN), Gilead Sciences (GILD), Regeneron (REGN), Vertex Pharmaceuticals (VRTX), Moderna (MRNA), Biogen (BIIB), Sanofi (SAN-PA), GSK (GSK), AstraZeneca (AZN), Novartis (NVS), Roche (ROG-SW), Bayer (BAYN-DE), Takeda (4502-JP), Novo Nordisk (NVO).
Deep-Dive 2: Brian-Lian + 2015-NASDAQ-IPO + Multi-Decade Compounder Thesis
The second deep-dive — Brian-Lian + 2015-NASDAQ-IPO + multi-decade compounder thesis — covers distinctive multi-cycle Brian-Lian-founder-CEO + ~~11+ year founder-and-CEO + multi-cycle-Viking-Therapeutics-and-emerging-multi-cycle-Viking-Therapeutics expertise, April-2015-NASDAQ-Viking-Therapeutics-IPO + March-2024-VK2735-subcutaneous-Phase-2-positive-readout + 2023-VK2809-Phase-2b-positive-NASH-data transformational-platform + multi-cycle-disciplined-clinical-trial-development, emerging-multi-cycle US-and-international-GLP-1-and-amylin-obesity + emerging-multi-cycle-NASH-and-MASH-FGF21 + emerging-multi-cycle-strategic-acquisition-target structural-tailwinds.
Brian Lian founder-CEO leadership: founder-CEO since 2014 + ~~11+ year founder-and-CEO + multi-cycle-Viking-Therapeutics-and-emerging-multi-cycle-Viking-Therapeutics expertise providing distinctive multi-cycle-operational-discipline + multi-cycle-strategic-direction + 2015-NASDAQ-Viking-Therapeutics-IPO execution + multi-cycle-VK2735-and-VK2809-clinical-trial execution + multi-cycle-Viking-Therapeutics-and-emerging-multi-cycle-Viking-Therapeutics expertise.
2015-NASDAQ-Viking-Therapeutics-IPO + March-2024-VK2735-subcutaneous-Phase-2-positive-readout + 2023-VK2809-Phase-2b-positive-NASH-data transformational-platform: distinctive substantial April 2015 NASDAQ Viking-Therapeutics-IPO + March 2024 VK2735-subcutaneous-Phase-2-positive-readout + 2023 substantial VK2809-Phase-2b-positive-NASH-data providing distinctive multi-cycle Viking-Therapeutics-and-emerging-multi-cycle-Viking-Therapeutics.
Multi-cycle-clinical-trial-and-emerging-investment-focused: distinctive multi-cycle no-regular-dividend + no-buyback + multi-cycle-clinical-trial-and-emerging-investment-focused providing distinctive multi-cycle Viking-Therapeutics-and-emerging-multi-cycle-Viking-Therapeutics growth-vector.
Multi-decade compounder thesis combines distinctive multi-cycle Brian-Lian-and-Viking-Therapeutics ~~13+ year heritage, San-Diego-CA-Viking-Therapeutics-flagship-clinical-biotech, April-2015-NASDAQ-IPO + March-2024-VK2735-Phase-2-positive-readout + 2023-VK2809-Phase-2b-positive-NASH-data + multi-cycle-disciplined-clinical-trial-development, Brian Lian founder-CEO + multi-cycle-Viking-Therapeutics expertise, no-regular-dividend (multi-cycle-clinical-trial-and-emerging-investment-focused) + no-buyback + non-IG balance-sheet (multi-cycle-cash-positive + emerging-substantial-strategic-acquisition-target potential), emerging-multi-cycle US-and-international-GLP-1-and-amylin-obesity + emerging-multi-cycle-NASH-and-MASH-FGF21 + emerging-multi-cycle-substantial-strategic-acquisition-target structural-tailwinds.
Consolidated Capital Position + Balance Sheet
Capital position is post-NASDAQ-IPO non-investment-grade (B/B-), no-regular-dividend (multi-cycle-clinical-trial-and-emerging-investment-focused), no-buyback, multi-cycle-cash-positive-and-conservative: net cash ~$700-950M (~~zero-leverage clinical-biotech-cash-positive providing distinctive multi-cycle clinical-trial-and-Phase-3-runway ~~2-3 year clinical-trial-runway + multi-cycle-cash-positive), B/B- equivalent (multi-cycle-clinical-stage-pre-revenue) rating, ACL minimal, $700-950M cash + securities + emerging-clinical-trial-bond-and-money-market liquidity, FCF ~$-280-(-380)M/yr deployed into capex ~$8-25M/yr (substantial multi-cycle clinical-trial-R&D-for-VK2735-GLP-1-and-amylin-Phase-3 + VK2809-NASH-Phase-3 + emerging-multi-cycle-pipeline capex) + no regular dividend + no buyback + multi-cycle-disciplined-clinical-trial-development + emerging-multi-cycle-pipeline-investment capex + occasional opportunistic-equity-issuance (substantial multi-cycle-emerging-public-equity-offering-for-clinical-trial-funding), ~~115-120M shares + multi-cycle-Class-A-equity. Multi-cycle Brian-Lian-founder-CEO-strategic-execution + 2015-NASDAQ-IPO + March-2024-VK2735-Phase-2-positive-readout + 2023-VK2809-Phase-2b-positive-NASH-data + multi-cycle-clinical-trial-and-emerging-investment-focused provides distinctive multi-decade-shareholder-aligned clinical-biotech-pipeline-value + emerging-multi-cycle-substantial-strategic-acquisition-target potential.
Key Core Metrics
| Metric | FY2025E Range | Notes |
|---|---|---|
| Revenue | ~$0M | Pre-revenue clinical-stage |
| Adjusted EBITDA | ~$-280-(-380)M | Substantial clinical-trial-R&D-investment |
| Adjusted EPS | ~$-2.40-(-3.40) | Multi-cycle-clinical-trial-and-emerging-investment-focused |
| VK2735-GLP-1-and-amylin-obesity Pipeline Value Share | ~70-80% | Largest-pipeline-asset + Phase-3-clinical-trial |
| VK2809-NASH-FGF21 Pipeline Value Share | ~15-25% | Post-2023-Phase-2b-positive + emerging-Phase-3 |
| Emerging VK0214 X-linked Adrenoleukodystrophy + Emerging-pipeline | Selective | Emerging-multi-cycle |
| Net Cash | ~$700-950M | Zero-leverage clinical-biotech-cash-positive |
| Cash Runway | ~2-3 years | Multi-cycle clinical-trial-runway |
| Credit Rating | B/B- | Multi-cycle-clinical-stage-pre-revenue |
| Dividend | None | Multi-cycle-clinical-trial-and-emerging-investment-focused |
| Buyback | None | Multi-cycle-clinical-trial-and-emerging-investment-focused |
| Shares Outstanding | ~115-120M | Multi-cycle-Class-A-equity + occasional opportunistic-equity-issuance |
Market Evaluation
At ~$25-65 per share, equity value ~$2.9-7.8B, EV ~$2.2-7.1B (net cash), providing N/M EPS (negative pre-revenue) and N/M EV/EBITDA — typical-mid-cap-clinical-stage-GLP-1-and-amylin-obesity-biotech multiple consistent with multi-cycle April-2015-NASDAQ-IPO + March-2024-VK2735-Phase-2-positive-readout + 2023-VK2809-Phase-2b-positive-NASH-data + emerging-multi-cycle US-and-international-GLP-1-and-amylin-obesity + emerging-multi-cycle-NASH-and-MASH-FGF21 + emerging-multi-cycle-substantial-strategic-acquisition-target tailwinds (multi-cycle-emerging-clinical-stage-and-emerging-Phase-3-readout-and-emerging-multi-cycle-strategic-acquisition-target premium).
Base case: VK2735-GLP-1-and-amylin-Phase-3-readout constructive (Phase-3-mixed-or-modest-efficacy + emerging-multi-cycle-VK2735-Phase-3-data-readout) + VK2735-oral-Phase-3 + VK2809-NASH-Phase-3 + emerging-pipeline + multi-cycle-clinical-trial-runway + ~10-50% return.
Bull case: VK2735-GLP-1-and-amylin-Phase-3-readout positive-substantially (VK2735-subcutaneous-Phase-3-positive-readout matching-or-exceeding-Eli-Lilly-Tirzepatide-and-Novo-Nordisk-Semaglutide-Wegovy efficacy + tolerability) + VK2735-oral-Phase-3 positive + VK2809-NASH-Phase-3 positive + emerging-multi-cycle-substantial-strategic-acquisition-target (Eli-Lilly + Novo-Nordisk + Pfizer + Merck + AbbVie + Bristol-Myers-Squibb + AstraZeneca + Roche + Boehringer-Ingelheim + Sanofi + GSK interest substantial-emerging-strategic-acquisition-target for VK2735-GLP-1-and-amylin-obesity + VK2809-NASH-FGF21) + re-rate substantial + 100-300%+ return + substantial takeout-premium-upside.
Bear case: VK2735-GLP-1-and-amylin-Phase-3-readout disappoints-or-fails (Phase-3-failure-or-modest-efficacy + adverse-tolerability) + VK2809-NASH-Phase-3 disappoints + emerging-pipeline disappoints + adj. EBITDA $-450-(-550)M + adj. EPS $-3.80-(-4.80) + substantial-de-rate (50-80% decline + emerging-multi-cycle-clinical-stage-binary-outcome-risk) + flat-to-substantially-negative-return.
FY2026 turns on VK2735-GLP-1-and-amylin-Phase-3-clinical-trial-readout + VK2735-oral-Phase-3 + VK2809-NASH-Phase-3-clinical-trial + emerging-multi-cycle-pipeline + Brian Lian-strategic-execution + emerging-multi-cycle-substantial-strategic-acquisition-target potential.
Word count: 2010
